Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne
Atlas Genetics reels in $20M in Series C round for rapid infectious disease tests
Clearside Biomedical, Inc. Completes $16 Million Series B Financing
Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine
Miramar Labs Secures $10 Million in Series D Funding
NovaDigm Therapeutics Raises $14M Series B to Support Phase 2 Trial of NDV-3 Vaccine
RusnanoMedInvest, Domain Associates and investor syndicate back ReVision Optics vision correction technology with $55 mln investment.
RusnanoMedInvest and Domain Associates to invest $93m in development of three next-generation pharmaceuticals.
Vladimir Gurdus: In order to foster the development of an innovative pharmaceuticals sector in Russia, we need the support of a globally competitive network of venture investors in the sector here in Russia.
Leonid Melamed: Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets.
Announcement of the first RusnanoMedInvest transaction - acquisition of shares of CoDa Therapeutics, Inc. (USA. CoDa is developing Nexagon, an innovative chronic wound healing solution with targeted applications in diabetic foot ulcers, venous leg ulcers and other chronic wound pathologies.
RUSNANO JSC and U.S. venture fund Domain Associates announced the launch of their joint investment program, as a result of which RusnanoMedInvestwas founded.
The agreement between RUSNANO JSC and Team Drive on the management and operation of the RusnanoMedInvest investment program was signed.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
15 December 2017
15 December 2017
14 December 2017